LXRX is a penny stock that has performed well over the last few weeks but looking at the chart, shares are trading within the gap zone. Volume this week compared to previous weeks is lower. Is that a concern or just a slow week? "Shares of LXRX stock have been on a tear for around a month. LXRX Stock Price, Forecast & News (Lexicon Pharmaceuticals) Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings data on Monday, April, 27th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.06. The biopharmaceutical company had revenue of $8 million for the quarter, compared to analysts' expectations of $7 LXRX Stock | LEXICON PHARMACEUTICALS Stock Price Today ... Jun 05, 2020 LXRX Stock News - Fidelity
LXRX Lexicon Pharmaceuticals, Inc. Common Stock. Data is currently not available. $1.95. 0.06 (3.17%) DATA AS OF Jun 05, 2020. Latest News. Why Lexicon Pharmaceuticals Stock Soared Today Apr 27, 2020.
Lexicon Pharmaceuticals - LXRX - Stock Price & News | The ... Lexicon Pharmaceuticals LXRX. LXRX. $1.91 -$0.01 -0.5% Price as of June 2, 2020, 4:30 p.m. EDT View Interactive LXRX Charts. A biopharmaceutical company focused on the discovery and development of (LXRX) News - STCK.PRO Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q4 results. Quarterly Results • Earnings per share came in at a loss of $0.48, which beat the estimate calling for a loss of $0.77. Get all the latest news for all your Stocktwits watchlist symbols in one click! Login with Stocktwits.
LXRX, Lexicon Pharmaceuticals Inc Seeking Alpha; Insider Trading Morningstar; Institutional Ownership Nasdaq; SEC Filings SEC; NBIX Tweets Stocktwits.
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price, Quote ... Lexicon Pharmaceuticals, Inc. (LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 - June 2, 2020). Recent News for $LXRX | Lexicon Pharmaceuticals ...
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 200.00% over the past year to ($0.63), which beat the estimate of ($0.69).Revenue of $7,999,000 lower by 13.21% from the same period last year, which beat the estimate of $7,790,000
6 Wall Street analysts have issued ratings and price targets for Lexicon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.53, suggesting that the stock has a possible upside of 136.91%. The high price target for LXRX is $9.00 and the low price target for LXRX is $2.10. Breaking News: LXRX latest news. - The Fly LXRX Lexicon $1.94 / -0.07 (-3.48%). 04/27/20 Lexicon announces anticipated near-term milestones 04/07/20 Lexicon to host virtual Annual Meeting of Stockholders 03/19/20 Brokerage Recommendations - Zacks Investment Research
Lexicon Pharmaceuticals, Inc. (LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 - June 2, 2020).
Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Stock ... Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. $LXRX Stock Technical Analysis | Lexicon | SwingTradeBot.com LXRX closed up 3.17 percent on Friday, June 5, 2020, on approximately normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected. Lexicon Pharmaceuticals - LXRX - Stock Price & News | The ...